Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Tokyo, Nov. 13 (Jiji Press)--Japan's Central Social Insurance Medical Council, which advises the health minister, approved ...

TOKYO, Nov 5, 2024 - (JCN Newswire ... contribute to strengthening the drug discovery venture ecosystem in Japan. Eisai and Eisai Innovation, Inc. are committed to utilizing their participation ...

Japanese stocks are higher in morning trade, led by gains in tech and real-estate stocks. Concerns about funding costs ease following the Fed’s rate cut overnight. Recruit Holdings is up 3.7% and ...

The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan. Read More on ESALF: Eisai NewsMORE Related Stocks Indices Commodities ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins ...

few more so than Eisai, which is developing a package of products and services in Japan for people living with dementia. Its latest venture is an alliance with Tokyo-based Lifenet Insurance Co ...